These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

674 related articles for article (PubMed ID: 33479538)

  • 21. Impact of obesity on COVID-19 patients.
    Yu W; Rohli KE; Yang S; Jia P
    J Diabetes Complications; 2021 Mar; 35(3):107817. PubMed ID: 33358523
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Low-grade inflammation, CoVID-19, and obesity: clinical aspect and molecular insights in childhood and adulthood.
    Muscogiuri G; Bettini S; Boschetti M; Barrea L; Savastano S; Colao A;
    Int J Obes (Lond); 2022 Jul; 46(7):1254-1261. PubMed ID: 35393519
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Metabolic dysfunction associated fatty liver disease and coronavirus disease 2019: clinical relationship and current management.
    Xu Y; Yang X; Bian H; Xia M
    Lipids Health Dis; 2021 Oct; 20(1):126. PubMed ID: 34602072
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The unique features of SARS-CoV-2 transmission: Comparison with SARS-CoV, MERS-CoV and 2009 H1N1 pandemic influenza virus.
    Wu Z; Harrich D; Li Z; Hu D; Li D
    Rev Med Virol; 2021 Mar; 31(2):e2171. PubMed ID: 33350025
    [TBL] [Abstract][Full Text] [Related]  

  • 25. MAFLD in COVID-19 patients: an insidious enemy.
    Dongiovanni P; Meroni M; Longo M; Fracanzani AL
    Expert Rev Gastroenterol Hepatol; 2020 Oct; 14(10):867-872. PubMed ID: 32705906
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Patients with Severe Obesity during the COVID-19 Pandemic: How to Maintain an Adequate Multidisciplinary Nutritional Rehabilitation Program?
    De Amicis R; Cancello R; Capodaglio P; Gobbi M; Brunani A; Gilardini L; Castenuovo G; Molinari E; Barbieri V; Mambrini SP; Battezzati A; Bertoli S
    Obes Facts; 2021; 14(2):205-213. PubMed ID: 33744894
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Obesity and the increased risk for COVID-19: mechanisms and nutritional management.
    Morais AHA; Passos TS; de Lima Vale SH; da Silva Maia JK; Maciel BLL
    Nutr Res Rev; 2021 Dec; 34(2):209-221. PubMed ID: 33183383
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Obesity and diabetes as high-risk factors for severe coronavirus disease 2019 (Covid-19).
    Zhou Y; Chi J; Lv W; Wang Y
    Diabetes Metab Res Rev; 2021 Feb; 37(2):e3377. PubMed ID: 32588943
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Melatonin is a potential adjuvant to improve clinical outcomes in individuals with obesity and diabetes with coexistence of Covid-19.
    El-Missiry MA; El-Missiry ZMA; Othman AI
    Eur J Pharmacol; 2020 Sep; 882():173329. PubMed ID: 32615182
    [TBL] [Abstract][Full Text] [Related]  

  • 30. COVID-19 severity in obese patients: Potential mechanisms and molecular targets for clinical intervention.
    Sharma JR; Yadav UCS
    Obes Res Clin Pract; 2021; 15(2):163-171. PubMed ID: 33509701
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Confluence of obesity and MAFLD during Covid-19 pandemic in a developing country.
    Gonzáles Yovera JG; Concepción-Zavaleta MJ; Coronado Arroyo J; Moreno Marreros D
    Endocrinol Diabetes Metab; 2021 Apr; 4(2):e00189. PubMed ID: 33173833
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Risk Factors for COVID-19: Diabetes, Hypertension, and Obesity.
    Buscemi S; Corleo D; Randazzo C
    Adv Exp Med Biol; 2021; 1353():115-129. PubMed ID: 35137371
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Emerging COVID-19 Neurological Manifestations: Present Outlook and Potential Neurological Challenges in COVID-19 Pandemic.
    Dewanjee S; Vallamkondu J; Kalra RS; Puvvada N; Kandimalla R; Reddy PH
    Mol Neurobiol; 2021 Sep; 58(9):4694-4715. PubMed ID: 34169443
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Obesity-Driven Deficiencies of Specialized Pro-resolving Mediators May Drive Adverse Outcomes During SARS-CoV-2 Infection.
    Pal A; Gowdy KM; Oestreich KJ; Beck M; Shaikh SR
    Front Immunol; 2020; 11():1997. PubMed ID: 32983141
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Obesity and Risk of COVID-19 Infection and Severity: Available Evidence and Mechanisms.
    Abiri B; Guest PC; Vafa M
    Adv Exp Med Biol; 2021; 1321():97-107. PubMed ID: 33656716
    [TBL] [Abstract][Full Text] [Related]  

  • 36. COVID-19: The Inflammation Link and the Role of Nutrition in Potential Mitigation.
    Zabetakis I; Lordan R; Norton C; Tsoupras A
    Nutrients; 2020 May; 12(5):. PubMed ID: 32438620
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [The endocrine and metabolic link between COVID-19, diabetes and obesity].
    Weis N; Thorsteinsson K; Martinussen C; Madsbad S
    Ugeskr Laeger; 2020 Jul; 182(29):. PubMed ID: 32734864
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Review of the Metabolic Risk Factors for Increased Severity of Coronavirus Disease-2019.
    Fishkin T; Goldberg MD; Frishman WH
    Cardiol Rev; 2021 Nov-Dec 01; 29(6):292-295. PubMed ID: 34261900
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Metabolic-associated fatty liver disease is associated with severity of COVID-19.
    Zhou YJ; Zheng KI; Wang XB; Sun QF; Pan KH; Wang TY; Ma HL; Chen YP; George J; Zheng MH
    Liver Int; 2020 Sep; 40(9):2160-2163. PubMed ID: 32573883
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2): a Systemic Infection.
    Synowiec A; Szczepański A; Barreto-Duran E; Lie LK; Pyrc K
    Clin Microbiol Rev; 2021 Mar; 34(2):. PubMed ID: 33441314
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 34.